相关实验视频

Updated: Jun 14, 2025

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

由于抗结核药物诱导的肝损伤引起的急性肝衰竭:最新情况

Ramesh Kumar¹, Abhishek Kumar², Sudhir Kumar²

¹Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, India. docrameshkr@gmail.com.

World journal of hepatology

|June 12, 2025

概括

结核病药物可能导致肝损伤 (AT-DILI),可能导致急性肝衰竭 (AT-ALF). 本综述涵盖了AT-ALF流行病学,风险因素,表现,预后和治疗选择.

科学领域:

肝病学肝病学是一种肝病学.
传染性疾病传染性疾病
药理学药理学是指药理学的学科.

背景情况:

结核病 (TB) 仍然是一个重大的全球卫生挑战,特别是在发展中国家.
第一线抗结核药物 (ATD) 是有效的,但具有肝毒性风险,导致ATD诱导的肝损伤 (AT-DILI).
AT-DILI的发病率在2%至28%之间,大约7%的病例进展为急性肝衰竭 (AT-ALF).

研究的目的:

为提供ATD诱导的急性肝衰竭 (AT-ALF) 的综合性审查.
讨论AT-ALF的流行病学,风险因素,临床表现,预后和管理.
突出了解AT-ALF对于有效结核病治疗和患者结果的重要性.

主要方法:

对ATD诱导的肝损伤和急性肝衰竭研究的文献综述.
综合流行病学数据,临床特征和治疗结果.
分析与AT-ALF相关的风险因素和患者人口统计数据.

主要成果:

在全球范围内,AT-DILI影响11.5%,而AT-ALF发生在这些患者的一个子集中.
AT-ALF不成比例地影响年轻女性,通常是在治疗开始后的八周内.
肝移植是AT-ALF的治疗选择,尽管选择性手术的结果更好.

结论:

AT-ALF是结核病治疗的严重并发症,需要仔细监测和管理.
早期识别和适当的干预,包括移植,对于改善生存率至关重要.
对风险分层和AT-ALF的新疗法策略进行进一步的研究是有必要的.

关键词:

严重的肝衰竭是急性肝衰竭.抗结核药物抗结核药物是一种抗结核药物.药物诱导的肝损伤是药物诱导的肝损伤肝毒性肝毒性肝毒性结核病是一种疾病.

更多相关视频

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

相关概念视频

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...